A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections

Clinical Infectious Diseases

Volumn 52, Issue SUPPL. 7, 2011, Pages

  Craft, J Carl ^a,e   Moriarty, Susan R ^d   Clark, Kay ^a   Scott, Drusilla ^a   Degenhardt, Thorsten P ^a   Still, J Gordon ^b   Corey, G Ralph ^c   Das, Anita ^c   Fernandes, Prabhavathi ^a  

^a Cempra Pharmaceuticals   (United States)

^b Fulcrum Pharma   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Axistat   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUSIDIC ACID; LINEZOLID;

ADULT; ARTICLE; BACTERIAL ENDOCARDITIS; CELLULITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN INFECTION; WOUND INFECTION;

ACETAMIDES; ACUTE DISEASE; ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; CELLULITIS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FUSIDIC ACID; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; SKIN DISEASES, BACTERIAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955780193     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir167     Document Type: Article

References (25)

1. Pasternack MS, Swartz MN. Cellulitis, necrotizing fasciitis and subcutaneous tissue infections. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed. Philadelphia, PA: Elsevier Churchill Livingston, 2010: Chapter 20.
2. Rammelkamp CH, Maxon T. Resistance of Staphylococcus aureus to the action of penicillin. Proc Soc Exp Biol Med 1942; 51:386-9.
3. Jevons MP. "Celbenin"-resistant staphylococci. Br Med J 1961; 1:124-5.
4. Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992; 13:582-6.
5. Bradley SF. Methicillin-resistant Staphylococcus aureus: long-term care concerns. Am J Med 1999; 106:2S-10S. (Pubitemid 29239276)
6. King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA clone 300 as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006; 144:309-17. (Pubitemid 46768185)
7. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-74.
8. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic and therapeutic odyssey. Clin Infect Dis 2005; 40:562-73. (Pubitemid 40270226)
9. Mandell LA. Fusidic acid. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed. Philadelphia, PA: Elsevier Churchill Livingston, 2010: Chapter 25.
10. Jones RN, Mendes RE, Sader HS, Castanheira M. In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States. Clin Infect Dis 2011; 52(Suppl 7):S477-86.
11. Tsuji BT, Okusanya OO, Bulitta JB, et al. Application of pharmaco-kinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dose regimen: raising lazarus from the dead. Clin Infect Dis 2011; 52(Suppl 7):S513-9.
12. Guidance for Industry. Acute bacterial skin and skin structure infections drugs for treatment. Rockville, MD: US Food and Drug Administration. 2010. Available at: http://www.fda.gov/downloads/ Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ UCM071185.pdf. Accessed 31 August 2010.
13. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46:S368-77. (Pubitemid 351717324)
14. Moellering RC. Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46:1032-7.
15. Klevins RM, Edwards JR, Tenover FC, et al. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006; 42:389-91. (Pubitemid 43122317)
16. Cohen PR. Community-acquired methicillin-resistant Staphylococcus aureus skin infections: a review of epidemiology, clinical features, management, and prevention. Int J Dermatol 2007; 46:1-11. (Pubitemid 46029718)
17. McCraig LF, McDonals LC, Mandal S, Jernigan DB. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis 2006; 12:1715-23. (Pubitemid 44674248)
18. Miller LG, Perdreau-Remington F, Bayer A, et al. Clinical and epide-miologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin- susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007; 44:471-82. (Pubitemid 46233247)
19. Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphyolococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37:1257-60. (Pubitemid 37372517)
20. Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46:584-93. (Pubitemid 351263501)
21. Collignon P, Turnidge J. Fusidic acid in vitro activity. Int J Antimicrob Agents 1999; 12(Suppl 2):S45-S58. (Pubitemid 29406141)
22. Turnidge J. Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 1999; 12(Suppl 2): S23-S34. (Pubitemid 29406139)
23. Rowling DE. Further experience in the management of chronic osteomyelitis. J Bone Joint Surg Br 1970; 52:302-7.
24. Coombs RRH. Fusidic acid in staphylococcal bone and joint infection. J Antimicrob Chemother 1990; 25(Suppl. B):53-60. (Pubitemid 20087267)
25. Farrell DJ, Castanheira M, Chopra I. Characterization of global patterns and the genetics of fusidic acid resistance. Clin Infect Dis 2011; 52(Suppl 7):S487-92.